WHO ICTRP trial
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With…
PER-080-06 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-080-06 |
|---|---|
| Public title | Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. |
| Scientific title | MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY OF DENOSUMAB COMPARED WITH ZOLEDRONIC ACID (ZOMETA) FOR THE TREATMENT OF BONE METASTASES IN SUBJECTS WITH ADVANCED CANCER (EXCLUDING BREAST CANCER AND PROSTATE) OR MULTIPLE MYELOMA |
| Primary sponsor | AMGEN INC., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | III |
| Countries | India;Israel;Germany;Austria;Belgium;Bulgaria;Latovia;Slovakia;Spain;France;Greece;Netherlands;Hungary;Italy;Lithuania;Poland;Portugal;United Kindgdom;Romania;Russian… |
| Conditions | -C80 Malignant neoplasm, without specification of site -C900 Multiple myeloma -C85 Other and unspecified types of non-Hodgkin lymphoma Malignant neoplasm, without specification of site Other and unspecified types of non-Hodgkin lymphoma… |
| Interventions | Group name:GROUP 1 Type of group;1 N° of participants:845 Intervention(s) description:This group will be treated with Denosumab, at a dose of 120 mg, SC, every 4 weeks + Zoledronic acid Placebo, in IV infusion not less than 15 minutes… |
| Registration date | May 23, 2007 |
| Target size | 25 |
| Secondary IDs | DRKS00003986;NCT00330759;2006-000848-65 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: